McLaren Macomb first in Southeast Michigan to offer Tomosynthesis 3D Breast Screening Technology

MOUNT CLEMENS, MI – McLaren Macomb is the first and only hospital in Southeast Michigan to offer women who undergo routine mammograms the latest screening and diagnostic technology available to them.

The McLaren Macomb Breast Center now offers 3D digital tomosynthesis for breast cancer screening. This three dimensional imaging technology produces a revolutionary type of mammogram by reconstructing a series of one-millimeter thick breast image slices into a 3D view of the breast.

This helps radiologists identify and characterize individual breast structures without the confusion of overlapping tissue. 

With the Selenia® Dimensions® breast tomosynthesis system made by Hologic, exceptionally sharp breast images are produced. The system is designed to deliver superior screening and diagnostic performance with an advanced ergonomic design, providing more patient comfort.

When combined with conventional 2D mammography, breast cancer screening with tomosynthesis has a higher cancer detection rate than conventional 2D mammography alone.   Radiologists are reporting that tomosynthesis technology gives them increased confidence with a significant reduction in recall rates.

“We are very proud to offer women this new advancement in breast cancer screening,” said Pat Keigher, director of the McLaren Macomb Breast Center and the Ted B. Wahby Cancer Center. “This new technology may be especially of interest to women who are at high risk for breast cancer or who have a family history of breast cancer,”

By offering women the latest technology in mammography, McLaren Macomb wants to increase the number of area women who will be routinely screened.  Breast cancer is the second leading cause of cancer death among women, exceeded only by lung cancer. Statistics indicate that one in eight women will develop breast cancer sometime in her lifetime. The stage at which breast cancer is detected influences a woman’s chance of survival. If detected early, the five-year survival rate is 98 percent.

For more information about 3D tomosynthesis breast screening, please visit www.mclaren.org/MacombBreastCenter.